Investors See Opportunity in Huge Global Demand for Lithium
The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.
Put this company on your investing radar today.
Laura Sepp-Lorenzino, insider at Intellia Therapeutics
Laura Sepp-Lorenzino Insider Alerts

Get notified the next time Laura Sepp-Lorenzino buys or sells Intellia Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Laura Sepp-Lorenzino Insider Information

Laura Sepp-Lorenzino oversees all platform and pipeline research activities across in vivo and ex vivo (engineered cell therapy) areas as Intellia’s Chief Scientific Officer. Before joining Intellia, she was vice president, Head of Nucleic Acid Therapies, Research, and member of the External Innovation team at Vertex Pharmaceuticals, Inc. She also served as vice president, entrepreneur-in-residence at Alnylam Pharmaceuticals, Inc., a leader in the development of RNAi Therapeutics. At Alnylam, she was responsible for the Hepatic Infectious Disease Strategic Therapeutic Area, championed extra hepatic siRNA delivery, and was active in licensing and partnering.

Laura spent 14 years at Merck & Co., most recently having served as executive director and department head, RNA Therapeutics Discovery Biology. In this role, she was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of preclinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Laura also has expertise in oncology drug discovery and development acquired earlier in her career by leading the Cancer Research Department at Merck West Point and working as an assistant lab member and assistant attending molecular biologist at Memorial Sloan-Kettering Cancer Center.

She received her professional degree in Biochemistry from the University of Buenos Aires, Argentina and both her M.S. and Ph.D. in Biochemistry from New York University. Laura holds professional affiliations with key scientific organizations, including the Oligonucleotide Therapeutics Society, the American Society for Gene and Cell Therapy, the European Society of Gene and Cell Therapy, and the New York Academy of Sciences, as well as a number of oncology societies. She also sits on the scientific advisory board of Thermo Fisher Scientific, Lodo Therapeutics, the U.K. Nucleic Acid Therapy Accelerator and is a member of Taysha Gene Therapies’ board of directors.

What is Laura Sepp-Lorenzino's net worth?

The estimated net worth of Laura Sepp-Lorenzino is at least $356,530.43 as of August 30th, 2021. Dr. Sepp-Lorenzino owns 3,191 shares of Intellia Therapeutics stock worth more than $356,530 as of November 30th. This net worth estimate does not reflect any other assets that Dr. Sepp-Lorenzino may own. Learn More.

What is Laura Sepp-Lorenzino's salary?

As the EVP of Intellia Therapeutics, Inc., Dr. Sepp-Lorenzino earned a total compensation package of $1,690,526.00 in 2020. Dr. Sepp-Lorenzino earned a salary of $420,000.00, a bonus of $184,800.00, options awards of $1,081,148.00, and other compensation of $4,578.00.

How do I contact Laura Sepp-Lorenzino?

The corporate mailing address for Dr. Sepp-Lorenzino and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]

Has Laura Sepp-Lorenzino been buying or selling shares of Intellia Therapeutics?

Laura Sepp-Lorenzino has not been actively trading shares of Intellia Therapeutics during the last quarter. Most recently, Laura Sepp-Lorenzino sold 97,000 shares of the business's stock in a transaction on Monday, August 30th. The shares were sold at an average price of $154.83, for a transaction totalling $15,018,510.00. Following the completion of the sale, the executive vice president now directly owns 3,191 shares of the company's stock, valued at $494,062.53.

Who are Intellia Therapeutics' active insiders?

Intellia Therapeutics' insider roster includes John Crowley (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), and Laura Sepp-Lorenzino (EVP).

Are insiders buying or selling shares of Intellia Therapeutics?

In the last year, insiders at the sold shares 34 times. They sold a total of 2,182,245 shares worth more than $212,298,922.99. The most recent insider tranaction occured on November, 5th when EVP David Lebwohl sold 2,400 shares worth more than $318,528.00. Insiders at Intellia Therapeutics own 3.9 % of the company.

Information on this page was last updated on 11/5/2021.

Laura Sepp-Lorenzino Insider Trading History at Intellia Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/30/2021Sell97,000$154.83$15,018,510.003,191View SEC Filing Icon  
8/4/2021Sell26,000$138.24$3,594,240.00View SEC Filing Icon  
See Full Table

Laura Sepp-Lorenzino Buying and Selling Activity at Intellia Therapeutics

This chart shows Laura Sepp-Lorenzino's buying and selling at Intellia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intellia Therapeutics Company Overview

Intellia Therapeutics logo
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $111.73
Low: $109.75
High: $117.60

50 Day Range

MA: $132.16
Low: $111.73
High: $155.26

2 Week Range

Now: $111.73
Low: $37.00
High: $202.73


604,926 shs

Average Volume

1,489,341 shs

Market Capitalization

$8.21 billion

P/E Ratio


Dividend Yield



Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing
The White House is scared of our country's lithium supply running out. That's why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who's gobbling up land in the lithium-rich Nevada desert.
Exec-Order 14017 Could Send This Company Skyrocket